Company Overview

  • Home
  • Company Overview

Established in September 2018 and have over all 3 years of experience as a Pharmaceuticals and marketing. We are able to establish a cordial relationship with the reputed vendors.We are able to extend our product range suiting customer's demands. We "Virdax Therapeutics Pvt. Ltd." built strong commercialization capabilities and is in a position to take on Suppliers, Marketing, Production, High Quality, Medicines, Atordax CV 10, Atordax CV 20, Atordax F, Clinidax 5, Clinidax 10, Clinidax T, Etodax, Gabavin NT, Glimidax M 0.3, Glimidax M1 forte, Glimidax M1, Glimidax M2 forte, Glimidax M2, Glimidax M3 forte, Glimidax M3, Glimidax MV 1.2, Glimidax MV 2.2, Glimidax PM2, Moxyvin CV 625 Inner, Moxyvin CV 625, Neurodax, Pregadin NT, Pregadin, Rosuvin F, Rosuwin gold 10, Rosuwin gold 20, Telmidax 20, Telmidax 40, Telmidax Trio, Temidax 40 H, Temidax AM, Virkal K2, Voglivin M 0.2 etc. Our offered products are going to serve the society & well-being for curing diseases to lead a happy healthy life. Our vision is to become the most preferred supply partner to our customers and achieve sustained growth, through consistent delivery of innovative, customer-centric, world-class quality products. We judge our success by our performance with regard to the communities in which we live and work and the environment in which our employees work.


Virdax Therapeutics Pvt. Ltd. is a Private incorporated in 2018. It is classified as Non-govt company and is registered at Registrar of Companies, Delhi. Its authorized share capital is Rs. 100,000 and its paid up capital is Rs. 100,000. It is inolved in Business activities.

Also involved in third party manufacturing of all type of pharmaceutical dosage forms like Tablets, Capsules, Ointments, Creams, Injections and syrups.

Virdax Therapeutics Pvt. Ltd.'s Annual General Meeting (AGM) was last held on 2019 and as per records from Ministry of Corporate Affairs (MCA).
Directors of Virdax Therapeutics Pvt. Ltd. are Dr. Srinivasulu and Dr.Rajkumar.